Opdivo

July 6, 2017

Mutation Burden and PD-L1 Levels Can Help Predict Patient’s Response to Opdivo, Study Finds

Genetic characterization and the detection of PD-1 ligand protein (PD-L1) levels in non-small cell lung cancers (NSCLC) can help oncologists identify those who may benefit the most from Opdivo (nivolumab) ... Read more

March 5, 2015March 5, 2015

FDA Grants Licensing Application To Opdivo For The Treatment Advanced Squamous NSCLC

News

Bristol-Myers Squibb recently announced that the FDA-provided Biologics Licensing Application (BLA) to Opdivo (nivolumab) to serve as treatment for advanced squamous non-small cell lung cancer (NSCLC) after earlier therapy. The company explores ... Read more

October 31, 2014November 18, 2014

Bristol-Myers Squibb NSCLC Treatment Results Announced

Lung cancer News, News

Results from Bristol-Myers Squibb Company’s phase 2 clinical trial CheckMate -063 studying Opdivo (nivolumab) in patients with advanced squamous cell non-small cell lung cancer (NSCLC) indicated a 15% objective ... Read more

October 9, 2014October 9, 2014

Collaboration Between Novartis And Bristol-Myers Squibb To Evaluate New Immunotherapy For NSCLC Treatments

News

A new clinical collaboration between Novartis and Bristol-Myers Squibb Company (BMS) has been announced to evaluate the effectiveness of three molecularly targeted compounds in combination with BMS’s Opdivo (nivolumab) ... Read more

October 1, 2014October 1, 2014

Nivolumab Lung Cancer Drug EMA Validation for Marketing Authorization Application

News

The first immune-checkpoint targeting drug for non-small cell lung cancer (NSCLC), Opdivo (nivolumab), was just validated by the European Medicines Agency (EMA) to review its Marketing Authorization Application (MAA), according ... Read more